Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

VidaMed v Prosurge

This article was originally published in The Gray Sheet

Executive Summary

Federal judge grants VidaMed summary judgment in support of the company's assertion that ProSurge infringes a VidaMed patent by "asking, encouraging and otherwise soliciting physicians" to use ProSurge's infringing Opal and Opal Flex products for treatment of benign prostatic hyperplasia. The California federal court rules that the VidaMed patent covered basic methods for treatment involving the use of one or more radiofrequency electrodes deployed transurethrally to ablate prostatic tissue
Advertisement
Advertisement
UsernamePublicRestriction

Register

MT010486

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel